0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Tracking of Second Primary Melanomas in Vemurafenib-Treated Patients FREE

Stephane Dalle, MD, PhD; Nicolas Poulalhon, MD; Sébastien Debarbieux, MD; Daniela Zaharia, MD; Martin C. Mihm, MD; Mario E. Lacouture, MD; Alyx Rosen, MD; Ashfaq A. Marghoob, MD; Klaus J. Busam, MD; Lauriane Depaepe, MD; Pierre-Paul Bringuier, DVM-PhD; Pauline Richez, MD; Jean-François Baurain, MD; Brigitte Bressac–de Paillerets, PharmD, PhD; Brigitte Balme, MD; Luc Thomas, MD, PhD
[+] Author Affiliations

Author Affiliations: Unit of Dermatology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France (Drs Dalle, Poulalhon, Debarbieux, Zaharia, and Thomas); Université Claude Bernard, Lyon (Drs Dalle, Zaharia, and Thomas); Cancer research center of Lyon, Lyon (Dr Dalle); Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts (Dr Mihm); Department of Medicine, Dermatology Service (Drs Lacouture, Rosen, and Marghoob), and Department of Pathology (Dr Busam), Memorial Sloan-Kettering Cancer Center, New York, New York; Unit of Pathology, Centre Hospitalier Lyon-Sud, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon (Drs Depaepe, Bringuier, and Balme); Departments of Dermatology (Dr Richez) and Oncology (Dr Baurain), Centre du Cancer, Cliniques Universitaires St Luc Université Catholique de Louvain, Brussels, Belgium; and Service de Génétique, Département de Biopathologie, Institut de Cancérologie Gustave Roussy, Villejuif, France, and INSERM, U946, Genetic Variation and Human Diseases Unit, Paris, France (Dr Bressac–de Paillerets).


JAMA Dermatol. 2013;149(4):488-490. doi:10.1001/jamadermatol.2013.21.
Text Size: A A A
Published online

Our research group1 recently reported the occurrence of second primary melanomas (SPMs) detected in patients with vemurafenib-treated metastatic melanomas. We report herein the changes observed, via routinely used diagnostic tools such as digital dermoscopy and reflectance confocal microscopy (RCM), in pigmented lesions in patients treated with vemurafenib.

All patients treated with vemurafenib, 960 mg twice daily, for metastatic V600E BRAF -mutated melanoma, underwent routine monthly total-body skin examination with dermoscopy and digital dermoscopy. The 5 initial cases were very briefly reported previously.1 Suspect or rapidly changing lesions were excised and submitted for pathologic examination by 2 dermatopathologists and externally by a third independent dermatopathologist.

Patients signed an informed consent for molecular testing and basic science research to be performed on skin samples. In vivo RCM was performed using the Vivascope 1500 (Lucid Inc). Mutation status was determined using a real-time polymerase chain reaction assay (Cobas 4800 BRAF V600 Mutation Test; Roche Molecular Systems). Patient DNA was subsequently retested with a validated 2-fold bidirectional Sanger sequencing method.

Eight patients diagnosed as having a second primary melanoma signed a written informed consent prior to undergoing germline mutational analysis of CDKN2A (exons 1α, 2 and 3), ARF (exon 1β), CDK4, and MITF genes. Institutional review board approval was also obtained (CCPPRB No. 01-09-05, Paris Necker).

Twenty-five SPMs were diagnosed in 120 patients. The delay of the SPM diagnosis after vemurafenib treatment initiation ranged from 4 to 42 weeks. The median delay was 14 weeks (Table).

Table Graphic Jump LocationTable. Patient and Melanoma Characteristics in Study Cases

All the patients tested were found to be negative for the melanoma-prone genes germline mutation.

Two changing lesions were first reported by the patients themselves (cases 1 and 2). These were found to be invasive melanomas (Breslow thicknesses, 0.7 and 0.65 mm, respectively). Among the 9 lesions removed on the basis of handheld dermoscopy examination, thicknesses ranged from in situ to 0.45 mm. Under digital dermoscopy, significant changes were noted in 21 cases during short-term follow-up. The observed changes usually did not affect the external diameter of the lesion but were subtle modifications affecting the pigmented or vascular pattern within a given lesion. Those changes were invisible by naked-eye examination. Among the 21 lesions removed on the basis of digital dermoscopy follow-up, 12 were melanomas (ranging from in situ to 0.3 mm Breslow thickness).

Forty-two lesions were examined by RCM following the observation of significant changes on digital dermoscopy. Nineteen of these were subsequently not excised because of the presence of a typical benign features, and they did not show any additional significant change on subsequent observations.

Twenty-one melanoma samples were genotypically tested for NRAS and BRAF mutations. All the cases were wild-type mutations for BRAF; 1 case was NRAS Q61R mutated.

The impact of BRAF inhibition on BRAF wild-type nevi or early melanomas remains unclear. Paradoxical activation of the RAF/MEK/ERK pathway by RAF kinase inhibitors through a CRAF activation sequence has been the major foreseeable effect determined from the in vitro studies conducted by Hatzivasilliou et al.2 Alternatively, vemurafenib-induced blockade of the BRAF pathway may favor alternate signaling pathways. Ultimately, although rare, HRAS mutations have been reported in pigmented lesions, and vemurafenib may enhance their malignant behavior.

The exact incidence of SPM in patients with metastatic melanoma is still debated. Recently, Murali et al3 reported in an Australian population a history of 2 melanomas in up to 10.8% of a cohort of patients with metastatic melanoma before and during a long-term follow-up period. In our series, as well as in the series reported by Zimmer et al,4 most of the melanomas developed within a few weeks of treatment and were detected at an early clinical stage. The first observations were made during a clinical trial comparing vemurafenib with dacarbazine. In contrast to our findings reported herein with vemurafenib-treated patients, in our earlier study, our group did not detect any SPM in the dacarbazine group,1 and both groups of patients underwent the same follow-up.

An effective strategy for early detection of new primary melanomas is needed because BRAF blocking agents are being evaluated in the adjuvant setting. Beyond handheld dermoscopy, digital dermoscopy is a powerful tool for detecting significant changes within multiple pigmented lesions.5

The occurrence of SPM alongside the remarkable therapeutic response of melanoma metastases with vemurafenib therapy reflects the heterogeneous response of melanocytic lesions to BRAF inhibitors. V600E BRAF -mutated melanoma metastases responded to therapy, whereas wild-type melanomas were activated.

ARTICLE INFORMATION

Correspondence: Dr Dalle, Service de dermatologie, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, Lyon, France (stephane.dalle@chu-lyon.fr).

Accepted for Publication: January 8, 2013.

Author Contributions: Dr Dalle had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Dalle, Lacouture, and Thomas. Acquisition of data: Dalle, Poulalhon, Debarbieux, Zaharia, Mihm, Rosen, Marghoob, Busam, Bringuier, Richez, Baurain, Bressac–de Paillerets, and Thomas. Analysis and interpretation of data: Dalle, Marghoob, Busam, Depaepe, Richez, Baurain, Balme, and Thomas. Drafting of the manuscript: Dalle, Lacouture, and Thomas. Critical revision of the manuscript for important intellectual content: Poulalhon, Debarbieux, Zaharia, Mihm, Rosen, Marghoob, Busam, Depaepe, Bringuier, Richez, Baurain, Bressac–de Paillerets, Balme, and Thomas. Obtained funding: Thomas. Administrative, technical, and material support: Dalle, Zaharia, Lacouture, Busam, Depaepe, Baurain, Balme, and Thomas. Study supervision: Dalle, Mihm, Busam, Baurain, and Thomas.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported in part by grants from Lyon 1 University, the Hospices Civils de Lyon, and the liguecontre le cancer du Rhone (Dr Thomas).

Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation.  N Engl J Med. 2011;365(15):1448-1450
PubMed   |  Link to Article
Hatzivassiliou G, Song K, Yen I,  et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.  Nature. 2010;464(7287):431-435
PubMed   |  Link to Article
Murali R, Field AS, McKenzie PR,  et al.  Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis.  Pathology. 2010;42(3):287-289
PubMed   |  Link to Article
Zimmer L, Hillen U, Livingstone E,  et al.  Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.  J Clin Oncol. 2012;30(19):2375-2383
PubMed   |  Link to Article
Guitera P, Menzies SW. State of the art of diagnostic technology for early-stage melanoma.  Expert Rev Anticancer Ther. 2011;11(5):715-723
PubMed   |  Link to Article

Figures

Tables

Table Graphic Jump LocationTable. Patient and Melanoma Characteristics in Study Cases

References

Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation.  N Engl J Med. 2011;365(15):1448-1450
PubMed   |  Link to Article
Hatzivassiliou G, Song K, Yen I,  et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.  Nature. 2010;464(7287):431-435
PubMed   |  Link to Article
Murali R, Field AS, McKenzie PR,  et al.  Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis.  Pathology. 2010;42(3):287-289
PubMed   |  Link to Article
Zimmer L, Hillen U, Livingstone E,  et al.  Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.  J Clin Oncol. 2012;30(19):2375-2383
PubMed   |  Link to Article
Guitera P, Menzies SW. State of the art of diagnostic technology for early-stage melanoma.  Expert Rev Anticancer Ther. 2011;11(5):715-723
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,303 Views
13 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs
JAMAevidence.com

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Melanoma

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Make the Diagnosis: Melanoma